Behfar Ehdaie

💥On behalf of co-investigators @claretempany @adamkibel_uro @qdtrinh and co-senior authors @geoffsonn Peji Ghanouni, we are excited to share the FINAL results of MR-guided HIFU Focal Therapy in men with intermediate risk prostate cancer. 1/8 thelancet.com/journals/lanon…

This is what I'm talking about @ #AUA26: The masters at focal therapy discuss the finer points at the "Essentials in Prostate Cancer Focal Therapy" Course. The field is maturing and it great to see data driven decision making to optimize care for our pts with prostate cancer.

@BehfarEhdaieMD Kicking off the @UrologyMSK focal therapy and targeted biopsy course @KoelisBx @FocalOneHIFU

Honored to join Urologic Oncology colleagues and lend a Pathology voice and insights to the proceedings of this meeting addressing Targeted Biopsy & Focal Therapy @BehfarEhdaieMD @MSKCancerCenter

🎯 Join us at @MSKCancerCenter for Advanced Techniques in Target Prostate Biopsy & Focal Therapy in Prostate Cancer Case-based interactive expert panels 📅 05/14/26 @ NYC 🗽🇺🇸 Perfect timing before heading to DC for #AUA2026 ✈️ 🚅 Free registration 🔗: mskcc.cloud-cme.com/course/courseo…

@marthpodi @ChiUroSociety Thank you to the @ChiUroSociety for an engaging evening of multidisciplinary presentations and insightful discussion in an elegant setting. Dr Belfield was a true pioneer and giant in medicine.

Great to have Dr. Behfar Ehdaie give the annual Belfield lecture at @ChiUroSociety tonight. Full house and great discussions!

@dipenjparekh @gonzomdphd Congratulations 🙌. Richly deserved.

Come join us for hopefully an engaging and balanced AUA Course reviewing key concepts in prostate cancer focal therapy. Distinguished faculty discuss their experience and reveal advanced techniques using all focal therapy technology in a lively case-based format #AUA25

The inaugural Masterclass in Robotic HIFU for Prostate Cancer is only one day away! We are excited to have focal therapy experts Pierre Halteh, MD, @AmirLebastchi, MD, @BehfarEhdaieMD and Pr. Sebastien Crouzet share their personal experience. @USC_Urology @FocalOneHIFU

@nyulangone @nyugrossman Congratulations Alec! Well deserved. #10538

We are thrilled to announce the appointment of Alec C. Kimmelman, MD, PhD, as the next Chief Executive Officer at @nyulangone and Dean of @nyugrossman effective September 1, 2025. Learn more: nyulangone.org/news/nyu-lango…

Now in Clin Genitourin Cancer by @UrologyMSK @SigridCarlsson @vinlaudonemd @TouijerKarim @easthamja @BehfarEhdaieMD et al: Quantification of Gleason Pattern 4 Metrics Identifies Pathologic Progression in Grade Group 2 Prostate Cancer on Active Surveillance sciencedirect.com/science/articl…

#GU Reporting Insights: #ProstateCancer Program Covers: 1) prework talks (now available online) and 2) live-streamed webinar on Jan 22, 2025. Please register and share! Big discounts for junior CAP members! #GUPath #Pathology 👇👇👇 education.cap.org/node/12787

Is it possible to conduct large randomized surgical clinical trials in a single institution? The answer is yes, say Andrew Vickers and colleagues, reporting their experiences at Memorial Sloan Kettering. @SCTorg @VickersBiostat @MSKCancerCenter @MSKBiostats @BehfarEhdaieMD

#SUO24 #Debate – Management of localized radiorecurrent #ProstateCancer: Salvage radical prostatectomy. Presentation by @BehfarEhdaieMD @MSKCancerCenter. Written coverage by @zklaassen_md @GACancerCenter > bit.ly/3VteScK @UroOnc

@jimhumd @seanmmcbride Some additional thoughts: most patients’ data classified as outcome failure are low vol GG2 (MR- invisible) in the opposite hemigland (not dx on initial bx); & patients have option to resume AS. We are preparing 5-yr tx failure data to provide more counseling info for physicians

@seanmmcbride I counsel using this evidence. FT incontinence and ED better than RP. Some opt for FT for functional outcomes over cancer control. Of note, our 43% 2-yr focal therapy treatment failure is similar to @BehfarEhdaieMD 40% for in bore HIFU, which had more restrictive entry criteria pic.twitter.com/XBwn4roXjw

This is great work, @jimhumd! In light of these data, where do you see a role for focal cryo in your practice? #pcsm

@uroegg Perfect is the enemy of good.

History repeats itself....... Prostate Cancers in the Prostate-specific Antigen Interval of 1.8–3 ng/ml: Results from the Göteborg-2 Prostate Cancer Screening Trial - European Urology europeanurology.com/article/S0302-…

@CGaffMD @MSKCancerCenter @eugene_pietzak @PCF_Science @UrologyCareFdn @UrologyMSK Congratulations! Well deserved; trailblazing collaboration between institutions and across departments. Looking forward to watching your career in academic urologic oncology launch.

Honored to receive the Chairman’s Award for Excellence in Clinic Research @MSKCancerCenter surgery graduation. Not possible w/o exceptional mentorship from @BehfarEhdaieMD Howard Scher Matt Dallos @eugene_pietzak + support from @PCF_Science @UrologyCareFdn @UrologyMSK Ravetch Lab

@seanmmcbride @HimanshuNagarMD @MSKCancerCenter Welcome to the team!! Excited to work together.

Thrilled that @HimanshuNagarMD will be coming to @MSKCancerCenter to lead our GU Radiation Oncology team. He's a brilliant clinical trialist, an outstanding clinician, and someone with an impressive track record of mentoring and cross-disciplinary collaboration. We're very lucky! #radonc #pcsm @DrRosenbergMSK @morr316 @BehfarEhdaieMD @UrologyMSK #MedTwitter

Come join us for hopefully an engaging and balanced AUA Course reviewing the role of focal therapy in prostate cancer & translating the outcomes of clinical trials in clinical practice. Agnostic of technology but esteemed faculty discussing experience with all FT devices. #AUA24

@ProtonStorey @DrSpratticus And, do these “reclassified” cancers detected with adv bx techniques impact oncologic outcomes. As you mentioned, rad onc prospective trials are reassuring. And, 10yr+ registry data in focal therapy also reporting >95% metastases free and >98% survival data @LondonProstate1

@ProtonStorey @DrSpratticus Fair points Mark. We should continue to push and improve outcomes in this emerging treatment modality. Thought provoking: we observed 25% misclassification on initial bx (high vol, MR/Bx) -how many patients referred to radiation onc are undertreated based on biopsy tx planning?

One of many sessions showing #AUA24 endorsing this non EBM treatment to the point they discuss focal as something to add to your armamentarium rather than get evidence to support its use, FDA approval, payer and guideline support, and most importantly, patient benefit. Come on AUA. One thing to remain silent (which was unfortunate), another to build out dozens of sessions/days on this. Awesome for women to gather, just wish it was for something to help patients (cystectomy, nephrectomy, RPLND, etc).